# Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

> **NCT03789006** · PHASE4 · UNKNOWN · sponsor: **University of Khartoum** · enrollment: 300 (estimated)

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **DRUG:** Antithymocyte Immunoglobulin (Rabbit)
- **DRUG:** Interleukin 2 Receptor Antagonist

## Key facts

- **NCT ID:** NCT03789006
- **Lead sponsor:** University of Khartoum
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-21
- **Primary completion:** 2022-03-21
- **Final completion:** 2024-03-21
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789006, "Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03789006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*